MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma

Epidermal growth factor receptor (EGFR) targeted therapies have shown limited efficacy in head and neck squamous cell carcinoma (HNSCC) patients despite its overexpression. Identifying molecular mechanisms associated with acquired resistance to EGFR-TKIs such as erlotinib remains an unmet need and a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Sci Rep
Auteurs principaux: Jain, Ankit P., Patel, Krishna, Pinto, Sneha, Radhakrishnan, Aneesha, Nanjappa, Vishalakshi, Kumar, Manish, Raja, Remya, Patil, Arun H., Kumari, Anjali, Manoharan, Malini, Karunakaran, Coral, Murugan, Saktivel, Keshava Prasad, T. S., Chang, Xiaofei, Mathur, Premendu Prakash, Kumar, Prashant, Gupta, Ravi, Gupta, Rohit, Khanna-Gupta, Arati, Sidransky, David, Chatterjee, Aditi, Gowda, Harsha
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906491/
https://ncbi.nlm.nih.gov/pubmed/31827134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-55208-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires